Innovative Therapeutics Rectify Pharma's focus on developing Positive Functional Modulators targeting membrane proteins presents a unique opportunity to collaborate with pharmaceutical companies seeking novel treatment mechanisms for diseases like liver, cardio-renal-metabolic, and neurodegenerative disorders.

Strategic Partnerships Recent collaborations with industry leaders such as Boehringer Ingelheim highlight Rectify's potential as a strategic partner for companies interested in expanding their pipeline of rare and complex disease treatments, especially in chronic kidney disease and hepatobiliary areas.

Growing R&D Capacity The company’s recent hiring of experienced biotech executives, including a new CMO, indicates active expansion of its research and development capabilities, creating opportunities for co-development and licensing deals.

Funding Strength With substantial funding of 100 million dollars and early revenue streams, Rectify Pharma is positioned to accelerate clinical development and attract partners interested in early-stage innovative biotech assets.

Market Engagement Participation in leading industry events and ongoing presentation of preclinical data enhance visibility, making Rectify Pharma a prime target for strategic alliances, licensing, and investment opportunities in the biotech sector.